Safety and efficacy of vismodegib in patients aged ≥65 years with advanced basal cell carcinoma

Because many patients with unresectable basal cell carcinoma (BCC) are aged ≥65 years, this study explores the efficacy and safety of vismodegib in these patients with locally advanced (la) or metastatic (m) basal cell carcinoma (BCC) in the ERIVANCE BCC trial and the expanded access study (EAS).We...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Anne Lynn S., Lewis, Karl D., Arron, Sarah T., Migden, Michael R., Solomon, James A., Yoo, Simon, Day, Bann-Mo, McKenna, Edward F., Sekulic, Aleksandar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342800/
https://www.ncbi.nlm.nih.gov/pubmed/27764798
http://dx.doi.org/10.18632/oncotarget.12660

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342800/
https://www.ncbi.nlm.nih.gov/pubmed/27764798
http://dx.doi.org/10.18632/oncotarget.12660

Ejemplares similares